Melinta Therapeutics, Inc. (NASDAQ:MLNT)

7.10
Delayed Data
As of Jun 22
 -0.35 / -4.70%
Today’s Change
5.20
Today|||52-Week Range
24.25
-55.06%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Year
Trend

2014

2015

2016

2017
Revenue and IncomeNet Revenues15.2M27.3M18.0M33.9M
 
 
 
 
 
Depreciation And Amortization76.3K69.2K51.0K451.0K
 
 
 
 
 
 
Operating ExpensesGross Income----------
General Expenses74.5M116.2M135.2M112.3M
 
 
 
 
 
Research And Development62.5M93.4M81.7M49.5M
 
 
 
 
 
Total Operating Expenses74.6M116.2M135.2M112.8M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-59.4M-88.9M-117.2M-78.9M
 
 
 
 
 
Extraordinary Credit119.7K0.000.00335.0K
 
 
 
Extraordinary Charge0.000.000.00-607.0K
 
 
Interest Expense On Debt2.4M2.2M1.2M7.6M
 
 
 
 
 
Other Expenses0.000.000.0027.8M
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-61.6M-91.1M-118.0M-58.9M
 
 
 
 
 
Preferred Dividend0.000.000.00-19.3M
 
 
Net Income-61.6M-91.1M-118.0M-58.9M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS6.8M8.7M10.1M3.6M
 
 
 
 
 
Shares To Calculate EPS Diluted6.8M8.7M10.1M3.6M
 
 
 
 
 
 
Earnings Per ShareEPS-$9.05-$10.45-$11.70-$21.86
 
 
 
 
 
EPS Diluted-$9.05-$10.45-$11.70-$21.86